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signifi cant cardiovascular morbidity and mortality ( 2–4 ). 
Several lines of evidence demonstrated that OSA is as-
sociated with dyslipidemia and accelerated atheroscle-
rosis ( 5–12 ). A randomized, placebo-controlled clinical 
trial of continuous positive airway pressure (CPAP) has 
shown that OSA treatment with CPAP markedly reduces 
postprandial hyperlipidemia ( 13 ). Postprandial hyper-
triglyceridemia may confer risk for myocardial infarc-
tion, isch emic heart disease, stroke, and death ( 14–20 ). 
Therefore, it is conceivable that postprandial hyperlipi-
demia contributes to the cardiovascular risk of OSA. 
The pathogenesis of postprandial hyperlipidemia in 
OSA is unknown. 
 We developed a mouse model of CIH, which mimics 
oxyhemoglobin desaturations in patients with OSA ( 21–23 ). 
Using this model, we have recently shown that CIH im-
pairs chylomicron clearance in mice and inhibits a key 
enzyme of triglyceride-rich lipoprotein clearance, lipo-
protein lipase (LPL), in adipose tissue ( 24 ). CIH also up-
regulated a potent LPL inhibitor, adipose angiopoietin-like 
protein 4 (Angptl4) ( 24 ). However, the effect of CIH on 
triglyceride (TG) uptake by adipose tissue has not been 
explored; contribution of other organs and tissues to li-
poprotein clearance during CIH is unknown. Finally, the 
role of Angptl4 in CIH-induced metabolic dysfunction 
has not been determined. 
 We hypothesized that CIH impairs TG uptake by adi-
pose tissue depots and other organs and tissues via Angptl4. 
We exposed C57BL/6J mice to CIH for four weeks while 
treating them with Angptl4-neutralizing antibodies (Ab) 
or placebo (vehicle solution) and examined plasma clear-
ance and tissue uptake of [H 3 ]triolein-Intralipid. 
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 After our results showed that CIH selectively suppresses TG 
uptake in the lungs (see Results), we aimed to determine TG up-
take by different cellular populations. For this purpose, 300 s af-
ter the retroorbital injection of [H 3 ]-labeled Intralipid, mice 
were perfused with 10 ml of ice-cold PBS through the right ven-
tricle, the lungs were infl ated with a dispase solution (BD Biosci-
ences, CA), isolated, and then digested at 37°C with an enzyme 
cocktail containing 5 mg of collagenase I and 1 mg of DNase I in 
1 ml of DMEM high-glucose medium per lung (Life Technolo-
gies, Grand Island, NY). CD11b magnetic beads were used to iso-
late macrophages in the cell suspensions according to the 
manufacturer’s protocol (Miltenyi Biotec, Auburn, CA) followed 
by CD146 magnetic bead incubation of the CD11b fl ow through 
fraction to isolate endothelial cells. Radioactivity of CD11b+, 
CD11b  CD146+, and CD11b  CD146  cells was measured in a 
scintillation counter and normalized per number of cells. 
 LPL activity in tissues 
 LPL activity in heparin eluates from the heart, lung, liver, 
spleen, BAT, epididymal, omental, subcutaneous, and retroperi-
toneal WAT, and skeletal muscle was performed according to 
Nilsson-Ehle and Schotz with minor modifi cation ( 24, 30 ). One 
unit of LPL activity was defi ned as the release of 1 mmol of free 
fatty acids (FFA) in 1 h per gram of tissue. 
 Real-time PCR 
 Total RNA was extracted from liver using Trizol (Life Technolo-
gies, Rockville, MD), and cDNA was synthesized using Advantage 
RT for PCR kit from Clontech (Palo Alto, CA). Real-time reverse-
transcriptase PCR (RT-PCR) was performed with primers from 
Invitrogen (Carlsbad, CA) and Taqman probes from Applied 
Biosystems (Foster City, CA). The sequences of primers and 
probes for mouse and human 18S were previously described ( 31 ). 
Mouse Angptl4 mRNA had been measured with the Applied Bio-
systems premade primers and probes. The primers and probes 
for mouse Angptl4 were designed based on the GenBank sequence 
NM_020581.2, forward primer 5 ′ -CAGGACTGGGATGGCAATG-3 ′ , 
reverse primer 5 ′ -GTGTCCTCACCCCCCAAAT-3 ′ , and the probe 
5 ′ -ATTGCTCCAATTTC-3 ′ . 
 Gene-specifi c primers of LPL (Mm00434770_m1) and CD36 
(Mm01135198_m1) were supplied by Applied Biosystems (Foster 
City, CA). The mRNA expression levels were referenced to 18S 
rRNA, and the values were derived according to the 2     Ct 
method ( 32, 33 ). 
 Western blot 
 The omental adipose tissue and lung tissues were homoge-
nized in RIPA buffer (Sigma, St. Louis, MO). SDS-PAGE and 
Western blot were performed using Bio-Rad precast gel system. 
Twenty micrograms of proteins were applied per lane. For CD11b 
detection, we used primary rabbit polyclonal antibody against 
mouse CD11b (Abcam, Cambridge, MA) and goat anti-rabbit 
HRP (KPL). For CD146 detection, we used primary rabbit mono-
clonal antibody against mouse CD146 (Millipore, Billerica, MA) 
and goat anti-rabbit HRP (KPL). Actin was detected with mouse 
monoclonal anti-actin antibody from Sigma (A3853) and goat 
anti-mouse-HRP (KPL). 
 Statistical analysis 
 All values are reported as means ± SEM after confi rming that 
all continuous variables were normally distributed using the Kol-
mogorov-Smirnov test. Statistical signifi cance for all comparisons 
was determined by two-way ANOVA with Bonferroni posthoc cor-
rection for multiple comparisons. All tests were two-sided, and 
the signifi cance level was established at  P < 0.05. 
 MATERIAL AND METHODS 
 Experimental animals 
 In the study, we used a total of 114 male C57BL/6J mice from 
Jackson Laboratory (Bar Harbor, ME), 6–8 weeks of age at the 
beginning of the experiments. Fifty animals were used for fasting 
plasma lipids, tissue LPL activity, gene expression, and protein 
measurements; 54 mice were used in the [H 3 ]-TG clearance ex-
periment; and 10 mice were used for [H 3 ]-TG clearance by differ-
ent cell populations of the lungs. Mice were fed with regular 
chow and exposed to CIH or intermittent air (IA) while being 
treated with Angptl4-neutralizing antibody or vehicle. The IA 
group was weight-matched to the CIH group by varying food in-
take as previously described ( 21 ). The study was approved by the 
Johns Hopkins University Animal Use and Care Committee and 
complied with Public Health Service (PHS) Policy on Humane 
Care and Use of Laboratory Animals ( 25 ). 
 Intermittent hypoxia and Angptl4 antibody treatment 
 Our mouse model of CIH that mimics the oxygen profi le 
observed in patients with OSA has been previously described 
( 21, 24 ). During each cycle of intermittent hypoxia, the FiO 2 
decreased from 21% to 6.5% over a 30 s period, followed by a 
rapid return to 21% over the subsequent 30 s period. This 
regimen of intermittent hypoxia induces oxyhemoglobin de-
saturations from 99% to 70% 60 times/hour ( 21, 26 ). A con-
trol group was exposed to an identical regimen of IA. CIH and 
IA were administered during the light phase (9 AM to 9 PM) 
to coincide with the mouse sleep cycle. The duration of expo-
sure was four weeks. During the exposure to IA or CIH, mice 
were treated with Angptl4-neutralizing Ab (14D12 monoclonal 
antibody, Lexicon Pharmaceuticals, Inc., The Woodlands, TX) 
( 27 ) in phosphate buffered saline (PBS) at 30 mg/kg (the Ab 
group) or with PBS alone (the vehicle group) once per week 
for four weeks . For tissue harvesting, mice were euthanized 
under 1–2% isofl urane anesthesia after a 4 h fast. All animal eu-
thanizing was performed between 12 PM and 2 PM, during the 
light phase. Blood was collected by retroorbital puncture. Heart, 
lung, liver, spleen, brown adipose tissue (BAT), epididymal (EPI), 
omental (OM), subcutaneous (SC), and retroperitoneal (RP) 
white adipose tissue (WAT), and skeletal muscle (quadriceps) 
were immediately snap-frozen in liquid nitrogen. Fasting plasma 
lipids were measured with total cholesterol and TG kits from 
Wako (Richmond, VA). 
 [H 3 ]triolein-Intralipid TG clearance and tissue uptake 
 Intralipid (20%, Kabi Pharmacia, Clayton, NC) was diluted 
in sterile PBS to a fi nal 5% concentration, labeled with 240 µCi 
of [H 3 ]triolein (Perkin-Elmer NET431001MC) as previously 
described ( 28, 29 ), and administered by retroorbital injec-
tion (100 µl). Blood samples were taken from the opposite 
retroorbital sinus 30, 150 and 300 s after the injection under 
1–2% isofl urane anesthesia. At the completion of the study 
(300 s after injection), mice were perfused with 10 ml of PBS 
through the left ventricle, heart, lungs, liver, spleen, BAT, 
OM, EPI, SC, and RP WAT, and skeletal muscle (quadriceps) 
were collected. Radioactivity of plasma and tissue homoge-
nates was determined directly (without prior lipid extraction) 
in a scintillation counter. The plasma TG clearance and tissue 
TG uptake were quantifi ed according to Augustus et al. with 
minor modifi cations ( 29 ). The plasma TG clearance was calcu-
lated as the ratio of plasma radioactivity at 150 s and 300 s to 
plasma radioactivity at 30 s. The tissue TG uptake was calcu-
lated as the ratio of the whole organ radioactivity to total 
plasma radioactivity 30 s after the injection of the label. 
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liver ( Fig. 3 , insert).  CIH signifi cantly decreased TG up-
take by BAT (by 44%), EPI WAT (by 64%), OM WAT (by 
48%), and SC WAT (by 77%,  Fig. 3 ). CIH decreased TG 
uptake by the lungs (56%), whereas heart, liver, and spleen 
were unaffected. Angptl4 depletion signifi cantly increased 
TG uptake by all adipose tissue depots, lungs (a 4.4-fold 
increase), and the spleen (a 2.2-fold increase), but the in-
hibitory effect of CIH on TG uptake in adipose tissue and 
lungs was still present, despite Ab treatment. Neither CIH 
nor Ab affected TG uptake by heart, liver ( Fig. 3 ), or skel-
etal muscle (quadriceps not shown). Adipose tissue and 
the lungs were the only tissues in which TG uptake was 
signifi cantly affected by both CIH and Angptl4. 
 Effects of CIH and Angptl4-neutralizing antibodies on 
tissue LPL activity 
 The highest LPL activity was detected in heart tissue, 
whereas, as expected, the lowest levels were in the liver, 
which does not express active LPL in the adult state ( 35 ). 
CIH signifi cantly decreased LPL activity in BAT, EPI, OM, 
SC, and RP WAT, and the lungs ( Fig. 4 ),  whereas heart, 
skeletal muscle, liver, and spleen were not affected. 
Angptl4-neutralizing Ab increased LPL activity in all adi-
pose tissue depots, lungs, liver, and spleen, but not in the 
heart and skeletal muscle tissue. Similar to the TG uptake 
data, adipose tissue and lungs were the only tissues in 
which LPL activity was signifi cantly affected by both CIH 
and Angptl4. In contrast to TG uptake, Angptl4 depletion 
completely abolished the inhibitory effect of CIH on LPL 
activity in WAT and lungs ( Fig. 4 ). 
 Effect of CIH on TG uptake by different cellular 
populations in the lungs 
 Given that the lungs accounted for a signifi cant fraction 
of TG uptake and that lung tissue was the only tissue, be-
sides adipose, in which CIH decreased TG uptake and LPL 
activity ( Figs. 3 and 4 ), we attempted to identify the cellu-
lar populations involved. We used CD11b as a macrophage 
marker ( 36, 37 ) and CD146 as an endothelial cell marker 
( 38–41 ) in single-cell suspension of the lungs from mice 
 RESULTS 
 Basic characteristics 
 CIH induced weight loss ( Table 1 ).  Mice exposed to IA 
were weight-matched to the CIH group and, therefore, 
there was no difference in body weight or food intake be-
tween the groups. Ab treatment had no effect on body 
weight or food intake. CIH decreased the amount of OM 
and SC WAT, whereas liver weight was increased, regard-
less of Ab treatment. Neither CIH nor Ab affected weight 
of EPI WAT, BAT, lungs, spleen, or the heart ( Table 1 ). 
 Effect of CIH on Angptl4, CD36, and LPL gene 
expression in different tissues 
 We have previously shown that CIH upregulates Angptl4 
mRNA and protein levels in epididymal WAT ( 24 ). In this 
study, CIH also upregulated Angptl4 in omental WAT (a 
3.2 ± 1.2-fold increase) and lung tissue (a 3.1 ± 0.8-fold 
increase), but not in BAT, subcutaneous WAT, heart or 
liver. mRNA levels of LPL and CD36, a fatty acid trans-
porter ( 34 ), were not altered by CIH. 
 Effects of Angptl4-neutralizing antibodies and CIH on 
fasting plasma lipids and TG clearance 
 CIH increased plasma fasting total cholesterol (TC) and 
TG levels ( Fig. 1 ).  Regardless of IA or CIH exposure, 
Angptl4 Ab decreased fasting TG and TC. Ab treatment 
did not diminish the effect of CIH on fasting TG ( Fig. 1A ), 
whereas the effect of CIH on fasting cholesterol was at-
tenuated ( Fig. 1B ). CIH signifi cantly delayed clearance of 
[H 3 ]triolein-Intralipid ( Fig. 2 ).  In the IA group, 25.6% ± 
2.3% of [H 3 ]triglyceride was detected in plasma 300 s after 
injection, whereas in the CIH group, 36.0% ± 5.2% of [H 3 ]
triglyceride remained in circulation at this time ( P < 0.05). 
Blocking Angptl4 with Ab accelerated the TG clearance, 
but the effect of CIH was still present. 
 Effects of CIH and Angptl4-neutralizing antibodies 
on TG uptake 
 TG uptake was detected in multiple organs and tissues 
300 s after the injection, with particularly high levels in the 
 TABLE 1. Food intake, body weight, and weights of adipose tissue depots and organs in C57BL/6J mice 
exposed to IA or CIH while treated with Angptl-4 antibody or vehicle for four weeks 
Characteristic IA - Vehicle IA - Ab CIH - Vehicle CIH - Ab
N 28 30 28 28
Mean food intake 
 (g/mouse/day)
2.94 ± 0.13 2.83 ± 0.11 3.22 ± 0.29 3.26 ± 0.28
Body weight (g):
Day 0 24.8 ± 0.5 25.5 ± 0.5 25.3 ± 0.6 25.9 ± 0.5
 Day 28 24.4 ± 0.4 24.8 ± 0.6 c 24.1 ± 0.4 c 24.5 ± 0.6 c 
EPI WAT (g) 0.49 ± 0.029 0.49 ± 0.028 0.44 ± 0.017 0.44 ± 0.023
OM WAT (g) 0.22 ± 0.013 0.20 ± 0.012 0.18 ± 0.010 a 0.18 ± 0.009 a 
RP WAT (g) 0.11 ± 0.008 0.10 ± 0.007 0.11 ± 0.006 0.12 ± 0.023
SC WAT (g) 0.38 ± 0.020 0.35 ± 0.020 0.32 ± 0.015 a 0.32 ± 0.015 a 
BAT (g) 0.23 ± 0.010 0.25 ± 0.020 0.21 ± 0.007 0.25 ± 0.016
Liver (g) 0.87 ± 0.027 0.86 ± 0.014 0.93 ± 0.019 b 1.00 ± 0.021 b 
Lung (g) 0.14 ± 0.003 0.13 ± 0.004 0.15 ± 0.006 0.14 ± 0.003
Spleen (g) 0.05 ± 0.003 0.06 ± 0.002 0.05 ± 0.002 0.06 ± 0.002
Heart (g) 0.12 ± 0.002 0.11 ± 0.002 0.11 ± 0.002 0.12 ± 0.002
 a P < 0.05 for the effects of hypoxia.
 b P < 0.001 for the effects of hypoxia.
 c P < 0.001 versus day 0 body weight.
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lipoprotein clearance. In addition, we report several other 
novel fi ndings. First, Angptl4-neutralizing antibody in-
creased LPL activity in all adipose tissue depots and 
lungs, abolishing the inhibitory effect of CIH. Second, 
Angpt4-neutralizing antibody increased TG uptake in all 
adipose tissue depots, but the inhibitory effect of CIH 
was not reversed, which suggests that CIH suppresses TG 
clearance via an Angptl4/LPL-independent mechanism. 
Third, pulmonary endothelial cells were responsible for 
the majority of the TG uptake in the lungs, and CIH in-
hibited TG uptake by pulmonary endothelial cells, but 
not by other lung cellular populations. 
 CIH and Angptl4 
 Consistently with our previous fi ndings ( 24 ), CIH sup-
pressed TG clearance. We have now shown that CIH-
induced suppression of LPL activity and TG uptake occurs 
in all adipose tissue depots as well as in the lungs. LPL in-
activation by CIH is likely attributable to upregulation of a 
potent LPL inhibitor, Angptl4 ( 43–50 ). The effect of CIH 
on LPL is posttranscriptional given that mRNA levels were 
unchanged, which is consistent with the effect of Angptl4. 
The N-terminus of Angptl4 binds to LPL anchored to the 
surface of endothelial cells, converting active LPL dimers 
to inactive monomers ( 43, 50, 51 ). We have previously 
shown that CIH induces Angptl4 in epididymal fat ( 24 ). 
In the present study, we report that the effect of CIH on 
Angptl4 is tissue-dependent, affecting OM fat and the 
lung, but not other tissues. Expression of Angptl4 is regu-
lated by hypoxia inducible factor 1 (HIF-1) ( 52–57 ). We 
have recently shown that CIH-induced upregulation of 
Angptl4 in visceral fat is abolished by heterozygous defi -
ciency of HIF-1  , whereas constitutive overexpression of 
HIF-1  increases Angptl4 levels ( 58 ). Although mecha-
nisms of selective upregulation of Angptl4 in OM and 
EPI WAT and lungs are unknown, we hypothesize that 
differential regulation of HIF-1  in different organs may 
play a role. 
 CIH, LPL, and TG uptake 
 Angptl4-neutralizing Ab completely reversed CIH-
induced inhibition of LPL in all WAT depots and the lung. 
Neutralizing Ab bind to specifi c epitope at the N-terminus 
euthanized 300 s after [H 3 ]triolein-Intralipid injection. 
CD11b  CD146+ pulmonary endothelial cells exhibited 
a greater than 4-fold TG uptake than CD11b+ cells and a 
greater than 10-fold TG uptake than CD11b  CD146  
cells, which included epithelial cells, stromal cells, lym-
phocytes, and other lung cells ( Fig. 5A ).  CIH decreased 
TG uptake by CD11b  CD146+ endothelial cells by 42%, 
whereas TG uptake by CD11b+ macrophages and by 
CD11b  CD146  cells was not affected ( Fig. 5A ). West-
ern blot confi rmed the absence of CD11b+ cells in the 
CD11b  CD146+ fraction, whereas CD11b+ macrophages 
could express CD146 ( 42 ) ( Fig. 5B ). Thus, pulmonary 
endothelial cells were predominantly responsible for the 
TG uptake in the lungs and susceptible to the inhibitory 
effect of CIH. 
 DISCUSSION 
 In this study, we examined mechanisms of triglyceride 
clearance impaired by CIH. The main novel fi nding of 
our study is that CIH inhibited TG uptake and LPL 
activity in all adipose tissue depots and lungs, delaying 
 Fig.  1. Effect of CIH and Angptl4-neutralizing antibodies on serum fasting levels of (A) TG and (B) TC. 
* P < 0.05 and  † P < 0.001 versus IA.
 Fig.  2. Effect of CIH and Angptl4-neutralizing antibodies on 
clearance of [H 3 ]triolein-Intralipid. Results are normalized to the 
plasma radioactivity 30 sec after injection according to Refs.  34, 72 . 
* P < 0.05 for the effect of CIH;  † P < 0.001 for the effect of Ab.
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from LPL-mediated lipolysis of TG-rich lipoproteins. 
CIH did not alter expression of an FFA transporter 
CD36 ( 34 ), but other FFA transporters could have been 
affected, including fatty acid binding and transport pro-
teins ( 60 ). CIH may affect nonreceptor-mediated FFA 
uptake. Another possibility would be that TG uptake is 
infl uenced by changes in tissue perfusion during hy-
poxic exposure. CIH activates sympathetic nervous sys-
tem ( 61–63 ), which can lead to peripheral vasoconstriction 
and relatively poor perfusion of adipose tissue ( 64, 65 ). 
Catecholamines can also inhibit LPL posttranscription-
ally ( 35, 66, 67 ). Interestingly, CIH-induced inhibition 
of LPL in BAT was minimally affected by Angptl4 Ab, 
of Angptl4, blocking its ability to inactivate LPL ( 27, 59 ). 
Our fi ndings implicate OM and lung Angptl4 in inhibition 
of LPL during CIH. Angptl4 Ab decreased fasting lipid lev-
els, accelerated TG clearance, and increased TG uptake by 
all adipose tissue depots and lung tissue, suggesting that 
Angptl4-mediated inhibition of LPL contributed to dys-
lipidemia of CIH. However, Angptl4 Ab-treated mice still 
exhibited decreased TG tissue uptake during CIH, despite 
restoration of LPL activity. The latter strongly suggests that 
inhibition of LPL is not the principal mechanism of im-
paired TG tissue uptake in hypoxic mice. What would 
be potential LPL-independent mechanisms? One possi-
bility is that CIH inhibited transport of FFA derived 
 Fig.  3. Effect of CIH and Angptl4-neutralizing antibodies on the [H 3 ]triolein-Intralipid uptake in OM, 
EPI, SC, and RP WAT, BAT, heart, lung, liver, and spleen 300 sec after injection. The results are normalized 
to the plasma radioactivity 30 sec after injection according to Refs.  34, 72 ). The liver data are depicted on the 
insert. * P < 0.05 and  † P < 0.001 for the effect of hypoxia. 
 Fig.  4. Effect of CIH and Angptl4-neutralizing antibodies on LPL activity in OM fat, EPI fat, SC fat, 
RP fat, BAT, heart, lung, liver, spleen, and muscle in C57BL/6J mice. * P < 0.05 and  † P < 0.01 for the 
effect of hypoxia. 
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 Conclusions 
 CIH induces postprandial hyperlipidemia by decreasing 
TG uptake in adipose tissue and the lungs. CIH inactivates 
adipose and lung LPL via upregulation of Angptl4. How-
ever, reversal of LPL inhibition with Angptl4-neutralizing 
Ab does not abolish CIH-induced impairment in TG up-
take. We conclude that CIH inhibits TG uptake in adipose 
tissue and the lungs primarily via an LPL-independent 
mechanism.  
 The authors are very grateful to Dr. David R. Powell of Lexicon 
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which could be ascribed to abundant sympathetic inner-
vations of BAT ( 68 ). We conclude that CIH induces dys-
lipidemia by suppressing lipoprotein clearance and TG 
uptake in visceral adipose tissue and the lungs primarily 
via an LPL-independent mechanism. 
 Role of the lungs in TG clearance during CIH 
 Liver, spleen, and the heart were responsible for sig-
nifi cant portion of TG uptake, but there was no effect of 
CIH. An unexpected fi nding of our study was that lungs 
contributed signifi cantly to lipoprotein clearance and 
that TG uptake by the lung was inhibited by CIH. 
 Could our results be infl uenced by a route of adminis-
tration of TG? TG were delivered via the retroorbital ve-
nous plexus, and consequently, to the superior vena cava, 
the right heart, and directly to the lungs. Chylomicrons 
formed from TG in fatty meal enter the systemic venous 
circulation with lymph fl ow via the thoracic duct. Thus, 
although the retroorbital route bypasses intestinal ab-
sorption, Intralipid pharmacokinetics resembles that of 
chylomicrons in fatty meal and should not have a major 
adverse impact on our results. TG-rich lipoproteins can 
be used for surfactant biosynthesis in the lungs ( 69, 70 ), 
but impact of CIH on surfactant biosynthesis has not 
been studied. 
 CD146+ CD11b  cells were responsible for the vast 
majority of TG uptake in the lung. CD146 is a validated 
marker of pulmonary microvascular endothelial cells 
( 38–41 ). Therefore, our data strongly suggest that pulmo-
nary microvascular endothelial cells participate in post-
prandial TG clearance. CIH inhibited TG uptake by the 
pulmonary endothelium ( Fig. 5 ). LPL inactivation was not 
a key mechanism suppressing TG clearance by the pulmo-
nary endothelium, because CIH decreased pulmonary 
TG uptake despite restoration of the enzyme activity with 
Angptl4-neutralizing Ab ( Figs. 3 and 4 ). We hypothesize 
that changes in pulmonary blood fl ow during CIH play a 
role. Hypoxic pulmonary vasoconstriction may decrease 
the area of the vascular bed available for TG uptake ( 71 ) 
and can be implicated in CIH-induced inhibition of TG 
clearance, independent of Angptl4. 
 Fig.  5. Effect of CIH on [H 3 ]triolein-Intralipid uptake by (A) CD11b+ cells, CD11b  CD146+ cells, and 
CD11b+ CD146+ cells isolated from the lungs of C57BL/6J mice 300 sec after injection. (B) CD11b and 
CD146 Western blot in CD11b+ cells (lane 1); CD11b  CD146+ cells (lane 2); and CD11b  CD146  cells 
(lane 3) isolated from single-cell lung tissue suspension. * P < 0.05 versus IA. 
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